Previous Article | Next Article ![]()
Molecular and Cellular Biology, May 2006, p. 3853-3863, Vol. 26, No. 10
0270-7306/06/$08.00+0 doi:10.1128/MCB.26.10.3853-3863.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.
*
Mao Mao,1,
Matthew Biery,1
Paul Warrener,1
Sammy Kim,1
Carolyn Buser,2
C. Gary Marshall,2,
Christine Fernandes,2,¶
James Annis,1 and
Peter S. Linsley1
Rosetta Inpharmatics LLC, 401 Terry Ave. N, Seattle, Washington 98109,1 Merck Research Laboratories, West Point, Pennsylvania 194862
Received 6 December 2005/ Returned for modification 23 December 2005/ Accepted 12 February 2006
|
|
|---|
|
|
|---|
KIF14 is a mammalian kinesin classified as an N-type, kinesin-3 family member based upon phylogenetic sequence analysis of its presumptive motor domain (16, 19). Our interest in KIF14 was piqued by the observation that elevated KIF14 expression is associated with poor-prognosis breast cancer (28). However, due to the limited functional annotation for KIF14 and its Drosophila orthologs, it is difficult to speculate on how KIF14 may contribute to breast cancer prognosis. Separate studies characterizing KLP38B, which is the KIF14 ortholog in Drosophila melanogaster, ascribed different functions to this kinesin. One study reported a role for KLP38B in chromosome segregation (17), while another reported a role in cytokinesis (21). In addition, the silencing of KIF14 in human cells by using endoribonuclease-prepared short interfering RNA (esiRNA) was reported to disturb chromosome congression and alignment, resulting in a prolonged delay at the metaphase-to-anaphase transition (33).
In this report, we have characterized the mitotic expression, subcellular localization, and function of human KIF14. We establish that the KIF14 motor domain exhibits microtubule-dependent ATPase activity and that KIF14 manifests the elevated mitotic expression and subcellular localization properties of a mitotic kinesin. In addition, siRNA-mediated silencing of KIF14 produced distinct phenotypes that could be linked to siRNA efficacy. Strong silencing of KIF14 prevented midbody cleavage, resulting in the formation of multinucleated cells. Less efficacious KIF14 siRNAs were found to elicit apoptosis of cells following entry into mitosis, during an attempt at cytokinesis, after binucleation due to cytokinesis failure, or after completion of cell division. Therefore, the data demonstrate that the silencing of KIF14 generates a multitude of mitotic phenotypes in which the efficacy of KIF14 silencing dictates the stage at which cell cycle progression is disrupted.
|
|
|---|
Cell culture and transfections. HeLa-S3, HCT116, and HEK-293T cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Invitrogen) at 37°C. For siRNA transfections, cells were seeded in six-well (9.60 cm2) culture dishes at a densities of 60,000 to 90,000 cells/well in 2 ml serum containing growth medium. Twenty-four hours after seeding, cells were transfected with 100 pmol of siRNA using Oligofectamine (Invitrogen) transfection reagent according to the manufacturer's protocol. Cells were incubated with transfection complexes under normal growth conditions until collection for analysis at specific time points posttransfection. All siRNA duplexes (Table 1) were purchased from Dharmacon (Lafayette, CO). Plasmid transfections of HEK-293T cells were performed on cells plated at 2 x 104 cells per well in an eight-well chamber slide (Lab-Tek) and cultured overnight in 10% fetal bovine serum (Invitrogen). Cells were transfected the following day with 1 µg plasmid DNA per well using TransIT 293 reagent (Mirus) in Opti-MEM medium (Invitrogen) according to the manufacturer's protocol and incubated overnight. The colony-forming capacity of siRNA-transfected HeLa-S3 cells was evaluated by plating cells at 100, 500, and 1,000 cells per well 48 h posttransfection followed by 2 weeks of uninterrupted culture before staining with crystal violet.
|
View this table: [in a new window] |
TABLE 1. Sense sequence of siRNA duplexes
|
Immunoblot analysis of KIF14 expression. Transfected cells were trypsinized, collected by centrifugation (5 min at 300 x g), and washed with phosphate-buffered saline. Cell pellets were resuspended in lysis buffer (20 mM Tris HCl [pH 7.6], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) containing 1x protease inhibitor mix (Roche Complete) and incubated for 10 min on ice. Following centrifugation (10 min at 10,000 x g), the supernatant was collected and the protein concentration was determined by using the Bio-Rad DC protein assay kit. Equivalent protein (25 µg/sample) was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on Bio-Rad ready gels (7.5% acrylamide or 4 to 15% acrylamide gradient). Proteins were transferred to a nitrocellulose membrane and blocked in TBST buffer (150 mM NaCl, 10 mM Tris-HCl [pH 7.6], 0.1% Tween 20) containing 5% nonfat dry milk (blocking buffer) for 30 min at room temperature. The membrane was then incubated with anti-KIF14 antibody (Abcam, Inc.; ab3746) diluted 1:1,000 in blocking buffer for 90 min at room temperature. After three washes in TBST, the membrane was incubated with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G antibody (Zymed) diluted 1:10,000 in blocking buffer for 45 min at room temperature. Following three washes in TBST, the membrane was incubated in chemiluminescence detection reagents (ECL Plus, Amersham) and the image was captured using a charge-coupled device camera (Kodak Image Station 440CF).
Immunofluorescence microscopy. HeLa-S3 and 293T cells cultured on glass chamber well slides were fixed and permeabilized as described previously (12) for 15 min in immunohistochemical buffer. Following fixation, cells were washed with TBST and incubated with primary antibody for 90 min at 37°C. Cells were washed in TBST prior to secondary antibody addition and incubation at room temperature for 1 h followed by washes in TBST supplemented with 10 µg/ml Hoechst in order to stain DNA. Samples were mounted with Fluoromount G (Southern Biotech) and visualized directly on a DeltaVision (version 3.5) deconvolution microscope (Applied Precision, Inc.) or an InCell Analyzer 1000 (GE Healthcare) by using DAPI (4',6'-diamidino-2-phenylindole), fluorescein isothiocyanate, and rhodamine-Texas Red-phycoerythrin filter sets for blue, green, and red, respectively.
Time-lapse microscopy. Live cells were monitored in eight-well coverslip bottom chamber slides beginning at 20 or 40 h posttransfection via time-lapse image capture using n a DeltaVision version 3.5 deconvolution microscope (Applied Precision, Inc.). The microscope was fitted with a humidified 37°C/5% CO2 incubation chamber (Solent Scientific) to maintain a suitable environment for sustained image collection. Bright-field images of 1,024 by 1,024 or 512 by 512 pixels (see video S3 in the supplemental material) were collected at 5-min time intervals. Multiple coordinates per treatment from the chamber wells were collected through a 20x lens objective, magnified to x30 with a x1.5 magnifier, for an overall duration ranging from 20 to 40 h. Select time intervals were linked to generate MPEG movies using SoftWoRx software (Applied Precision, Inc.).
Cell synchronization by thymidine block. A double-thymidine block was used to synchronize HCT116 cells seeded in 10-cm plates at 1.5 x 106 cells per plate and grown overnight as previously described (29). After the second thymidine block, cells were washed and put into deoxycytidine medium; this process was designated as time zero. Samples were collected for flow cytometry, and RNA extraction was performed at 2-h intervals from time zero to 24 and 36 h.
Molecular profiling of synchronized HCT116. Cell lysates were homogenized using QIAshredder spin columns and total cellular RNA was isolated using the RNeasy mini kit (QIAGEN). RNA amplification, labeling, and hybridization to hu25K ink-jet DNA microarrays was carried out as previously described (10, 28).
Cell cycle analysis. To analyze cell cycle profiles, approximately 1 x 105 to 5 x 105 cells were harvested along with their accompanying medium and pelleted by centrifugation in order to obtain both adherent and detached cells for subsequent analysis. Ethanol-fixed cells were prepared for flow cytometry as previously described (24). For each sample, 10,000 events were collected using a FACSCalibur flow cytometer (Becton Dickinson) and incorporation of propidium iodide was used as a marker for DNA content. Aggregated cells were gated out, and cell cycle profiles were analyzed using FlowJo cytometry analysis software (version 4.0.2).
Expression and purification of recombinant KIF14 motor domain. A KIF14 gene fragment encoding amino acids V342 through to K720 was PCR amplified from cDNA clone KIAA0042 and cloned into pET22b (Novagen) using NdeI and XhoI sites engineered into the PCR primers. Escherichia coli BL21 (DE3) was transformed and cultured for 50 h at 18°C in LB broth containing 2 mM MgCl2 and 50 µg/ml carbenicillin. Harvested cells (20 g) were suspended in buffer (20 mM Tris-Cl [pH 8.0], 300 mM NaCl, 0.1% Tween, 10 mM imidazole, 2 mM MgCl2, 5 mM ß-mercaptoethanol) and lysed by French press. The sample was clarified and batch bound to 0.3 ml nickel-nitrilotriacetic acid (QIAGEN). Bound proteins were eluted by applying a step gradient of lysis buffer containing imidazole and analyzed by SDS-PAGE. Fractions were pooled, diluted 10-fold with cation exchange buffer (50 mM HEPES [pH 6.8], 1 mM MgCl2, 1 mM EDTA, 10 µM ATP, 1 mM dithiothreitol), and applied to a 1.0-ml HiTrap SP HP (Amersham Biosciences). Protein was eluted with a linear gradient to 750 mM KCl and analyzed by SDS-PAGE. Pooled fractions were diluted with buffer to 200 mM KCl, concentrated in a Centricon-30 concentrator, and spiked with glycerol to 10% vol/vol for storage at 70°C.
ATPase activity assay. Taxol-stabilized microtubules were prepared as described previously (13) and stored at 20 µM at room temperature. ATPase activity reactions (50 µl) contained 50 mM (PIPES) piperazine-N,N'-bis(2-ethanesulfonic acid) (pH 7.0), 1 mM EGTA, 1 mM dithiothreitol, 100 µg/ml bovine serum albumin, 2 mM MgCl2, 1 mM NaATP, 150 nM KIF14 motor domain, and differing amounts of taxol-stabilized microtubules. Reactions were incubated for 0 to 20 min at room temperature and quenched with 50 µl stop solution (1.8 M KCl, 50 mM EDTA). Propidium iodide was detected by addition of Quinaldine Red-ammonium molybdate.
|
|
|---|
![]() View larger version (30K): [in a new window] |
FIG. 1. KIF14 contains an internal motor domain with plus-end-directed determinants and microtubule-dependent ATPase activity. (A) The ATPase activity of a fragment corresponding to the KIF14 motor domain was assayed as described in Materials and Methods. The ATPase activity of the KIF14 motor (rate [V] per enzyme [E])/min is graphed as a function of microtubule (MT) concentration. (B) The polypeptide chain of KIF14 contains several distinct domains that are likely to be involved in regulating aspects of KIF14 function in vivo. The internal motor domain contains the highly conserved catalytic core (shown in dark gray) and the N-type conserved neck region (N). In addition to the coiled-coil region predicted to exist within the neck, KIF14 contains four additional regions predicted to form coiled-coil regions, CC1 to CC4 (hatched lines). The KIF14 forkhead-associated domain is bordered by CC1 and CC2. (C) The KIF14 neck linker contains the consensus N-type motor sequence K/RXIXNXXXV/IN found in other N-type kinesins (KIF11, KIF5B, and CENPE). In addition, KIF14 contains the N-type neck coiled-coil sequence -XX(X)- -XXX- -XX- , where denotes a highly conserved hydrophobic residue (shaded in gray and shown in bold type). The plus-end-directed classifications of both KIF14 and KLP38B are putative and have not been biochemically confirmed. +, positive motor polarity; ND, not determined.
|
![]() View larger version (28K): [in a new window] |
FIG. 2. The mitotic accumulation of KIF14 and its cell cycle-regulated expression mirrors that of known mitotic kinesins. (A) Microarray profiling and cell cycle analysis were used to correlate changes in gene expression with distinct stages of the cell cycle in synchronized HCT116 cells sampled at 2-h intervals after release from a double-thymidine block. The percentage of cells resident within G2/M at each time point is defined by DNA content as determined by flow cytometry (primary y axis), and the relative amount of KIF14 mRNA at each time point is defined as the log10 ratio as determined by microarray analysis (secondary y axis). (B) The expression of various mitotic and nonmitotic kinesins was compared with that of KIF14.
|
![]() View larger version (53K): [in a new window] |
FIG. 3. Changes in KIF14 localization coincide with distinct cell cycle stages. Immunofluorescence microscopy was used to evaluate the localization of exogenously expressed KIF14-EGFP in HEK-293T cells and endogenously expressed KIF14 in HeLa cells. (A) Analysis of KIF14-EGFP in a single cell. (B) Localization of exogenously expressed KIF14-EGFP in separate cells at distinct stages of mitosis. (C) Localization of endogenously expressed KIF14 in separate cells at distinct stages of mitosis. DNA staining (Hoechst), blue channel; KIF14 localization, green channel; -tubulin localization, red channel.
|
![]() View larger version (33K): [in a new window] |
FIG. 4. Distinct changes in ploidy are linked with KIF14 siRNA efficacy. (A) HeLa cells transfected with KIF14-specific moderate and strong siRNAs, M-1, M2, S-1, S-2, and S-3, were analyzed by flow cytometry 72 h after transfection. The DNA content of KIF14-specific siRNA-transfected cells is compared to that of cells transfected with a luciferase-specific siRNA. (B) Cells transfected with either of two polyploid-inducing KIF14-specific siRNAs (S-1 or S-2) were analyzed by immunofluorescence microscopy at 72 h after transfection. Staining with -tubulin and Hoechst allowed the evaluation of nuclear morphology of single cells. A total of 100 cells were evaluated for each siRNA duplex, and the number of mononuclear, multinuclear, and mitotic cells was compared to those of a luciferase (Luc) siRNA control. (C) HeLa cells were transfected with a panel of KIF14-specific siRNAs linked to different ploidy phenotypes as described in Fig. 4A. Cells were harvested 24 h after transfection, and equal amounts of protein were analyzed by immunoblotting with anti-KIF14 antibody. Cells transfected with an siRNA targeting luciferase, a gene not expressed in mammalian cells, served as the negative control. Those siRNAs that reduced KIF14 expression by less than 50% are labeled as moderate. Those siRNAs that reduced KIF14 expression more than 80% are labeled as strong. The percent of KIF14 remaining for each sample was calculated using Oct1 as a load control.
|
Time-lapse microscopy reveals multiple cell cycle defects associated with KIF14 silencing. Time-lapse microscopy was utilized to characterize the fate of HeLa cells transfected with either a strong or a moderate KIF14 siRNA. The single prominent phenotype associated with strong silencing of KIF14 was failure to complete cytokinesis. Cells transfected with strong siRNAs were able to segregate chromosomes, proceed through anaphase, initiate furrow formation, ingress the furrow and elongate the midbody in manners similar to those of luciferase siRNA controls (Fig. 5 and 6; see Videos S1 and S2 in the supplemental material). However, midbody cleavage did not occur in KIF14-depleted cells, resulting in midbody collapse and binucleated cells (see Video S2 in the supplemental material). The only marked difference we observed between control and KIF14-depleted cells when staining for KIF14 was a significant reduction in the concentration of KIF14 at the midbody of late-stage mitotic cells (Fig. 5). The inability of KIF14-depleted cells to complete cytokinesis is consistent with the increase in ploidy observed by both flow cytometry and microscopy (Fig. 4B; see Fig. S2 in the supplemental material). In addition, extensive endoreduplication was toxic to HeLa cells in long-term colony-forming assays as multinucleate cells were observed to undergo apoptosis after subsequent failed attempts at mitosis (unpublished data).
![]() View larger version (31K): [in a new window] |
FIG. 5. Strong silencing of KIF14 eliminates midbody concentration of KIF14 but does not prevent chromosome segregation, progression to telophase, or furrow ingression. Immunofluorescence microscopy was used to evaluate chromosome segregation and furrow ingression in KIF14 siRNA-transfected HeLa cells. DNA staining (Hoechst), blue channel; KIF14 localization, green channel; -tubulin localization, red channel. A, anaphase, T, telophase, C, cytokinesis.
|
![]() View larger version (107K): [in a new window] |
FIG. 6. Strong silencing of KIF14 prevents midbody cleavage and induces cytokinesis failure. HeLa cells were transfected with either a luciferase-specific siRNA (A) or the S-1 KIF14-specific siRNA (B). Twenty hours posttransfection, time-lapse imaging was initiated and images were generated at 5 min intervals for 20 h. The elapsed time for each sequence of images is denoted in minutes with the initial image set at time (T) zero.
|
|
View this table: [in a new window] |
TABLE 2. Penetrance of apoptotic phenotypes associated with moderate KIF14 silencinga
|
![]() View larger version (110K): [in a new window] |
FIG. 7. Moderate silencing of KIF14 induces apoptosis at multiple points in the cell cycle. HeLa cells were transfected with M-1 KIF14-specific siRNA and time-lapse imaging was initiated at 20 h posttransfection (A, B, and C) or 40 h posttransfection (D). Apoptosis can be seen to occur after failed cytokinesis and binucleation (A), prior to progression beyond metaphase (B), during an attempt at cytokinesis (C), and after completion of cytokinesis (D). Images were generated at 5 min intervals for 20 h, and for each sequence of images, the initial image is denoted as time (T) zero.
|
|
|
|---|
The effects of KIF14 silencing in HeLa cells that we observed differ from what was reported to occur in response to esiRNA-mediated silencing of KIF14 (33). Specifically, an esiRNA pool targeting KIF14 was shown to disrupt chromosome congression and alignment, resulting in a prolonged delay at the metaphase-to-anaphase transition (33). Moreover, this study did not report an increase in apoptosis or a defect in cytokinesis nor did a study that reported the absence of any mitotic phenotype in response to siRNA-mediated silencing of the KIF14 ortholog KLP38B in Drosophila S2 cells (7). However, mutants in KLP38B have been linked with cytokinesis failure (21) and defects in chromosome segregation (17). It is important to point out that, in the Drosophila S2 cell experiments, siRNA efficacy was not determined as experiments evaluating mRNA or protein knockdown were not reported (7). Additionally, the mRNA silencing reported for the KIF14 esiRNA pool used by Zhu et al. was approximately 60%, moderate by our definition, but how this reduction in mRNA affected protein levels was not evaluated (33). Furthermore, given the limitation that each siRNA duplex exhibits a unique "off-target" gene expression profile when introduced into a cell (11), the validation of phenotypes obtained by using siRNA pools is best confirmed by reproducing the phenotype with multiple single siRNAs.
Our experiments do not confirm a role for KIF14 in chromosome congression and alignment as we did not observe the metaphase-to-anaphase delay described by Zhu et al. despite testing several KIF14 siRNAs with different efficacies. Importantly, we show by using multiple siRNAs that, in response to strong KIF14 silencing, HeLa cells progress unimpeded through mitosis and are able to initiate furrow formation and ingression. However, these cells were unable to cleave the intracellular bridge connecting the dividing cells, resulting in midbody collapse, cell fusion, and binucleation. Together, these data support a role for KIF14 during cell abscission.
In addition to cytokinesis failure, we observed an increase in cell death in response to moderate KIF14 silencing that is preceded by an increase in annexin V staining confirming death by apoptosis (unpublished data). Time-lapse microscopy revealed that cell death in response to moderate KIF14 silencing occurred at three distinct points: prior to anaphase, during cytokinesis, or after mitotic exit. It is difficult to speculate as to why moderate KIF14 silencing is able to trigger this acute apoptotic phenotype, while the predominant, immediate effect caused by strong KIF14 silencing is cytokinesis failure. One possibility is that KIF14 may indirectly, through some yet-to-be-defined cargo, serve to enable the function of a mitotic sensor able to elicit an apoptotic signal in response to mitotic spindle abnormalities. Such a sensor function could operate throughout mitosis and would be diminished or eliminated as a consequence of strong KIF14 silencing. Importantly, the link we observed between siRNA efficacy and phenotypic outcome indicates that different stages of the cell cycle can be disrupted by changing the level of KIF14 expression and this could explain the diversity of phenotypes reported for both KIF14 (33) (this report) and its Drosophila ortholog (21) (17).
Our characterization of KIF14 as a mitotic kinesin may be functionally significant to its identification as a poor-prognosis breast cancer gene (28). Our data are consistent with the hypothesis that elevated expression of KIF14 serves as a reporter for highly proliferative cancers as increased proliferation has been shown to strongly correlate with poor-prognosis breast cancer (27). Alternatively, the recent identification of KIF14 as a candidate oncogene (4) raises the interesting possibility that mitotic spindle or cytokinesis defects that might result from KIF14 overexpression could lead to increased genetic instability and progression towards aneuploidy in certain cell types or genetic backgrounds (6, 20). It will be important to determine whether the elevated expression of KIF14 serves to promote oncogenesis, as this would warrant evaluation of KIF14 as a target for new antineoplastic compounds.
|
|
|---|
Supplemental material for this article may be found at http://mcb.asm.org/. ![]()
These authors contributed equally to this work. ![]()
Present address: Merck Research Laboratories, Boston, MA 02115. ![]()
¶ Present address: GlaxoSmithKline Pharmaceuticals, Collegeville, PA 19426. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»